海翔药业(002099) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥602,322,185.59, a decrease of 6.52% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2021 was ¥16,154,263.23, down 83.23% year-on-year[2] - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥8,647,050.48, a decline of 90.72% compared to the previous year[2] - The company reported a net profit of ¥236,368,282.43 for the first nine months of 2021, a year-on-year decline of 34.69%[5] - Total operating revenue for the period was CNY 1,791,189,626.72, a decrease of 8.25% compared to CNY 1,952,137,248.80 in the previous period[32] - Net profit for the period was CNY 75,496,022.12, a significant decrease of 79.21% compared to CNY 361,927,913.47 in the previous period[34] - The total comprehensive income for the period was CNY 75,034,575.47, a decrease of 79.25% from CNY 362,072,233.10 in the previous period[38] Cash Flow and Liquidity - The operating cash flow for the year-to-date period was ¥349,404,335.85, a decrease of 32.92%[2] - Net cash flow from operating activities decreased by 32.92% to approximately ¥349.40 million, mainly due to increased payments for purchased goods[10] - Cash inflow from investment activities is ¥6,275,839.01, compared to ¥350,700.00 in the previous period, showing a significant increase[42] - Net cash flow from investment activities is -¥481,222,299.25, worsening from -¥78,806,707.36 in the previous period[42] - Cash inflow from financing activities is ¥700,527,390.00, up from ¥240,000,000.00 in the previous period, representing an increase of approximately 192.8%[42] - Net cash flow from financing activities is ¥186,129,373.82, a turnaround from -¥434,630,861.39 in the previous period[42] - The ending cash and cash equivalents balance is ¥1,983,605,703.38, an increase from ¥1,518,244,679.54 in the previous period[42] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,852,606,837.17, an increase of 9.39% from the end of the previous year[2] - The total assets of the company reached ¥7,852,606,837.17 as of September 30, 2021, compared to ¥7,178,568,316.07 at the end of 2020, indicating an increase of about 9.4%[25] - The total liabilities increased to CNY 1,788,824,579.90, up 34.83% from CNY 1,326,499,002.45 in the previous period[31] - The total equity attributable to shareholders of the parent company rose to CNY 6,064,963,422.21, an increase of 3.62% from CNY 5,852,085,567.11 in the previous period[31] Investments and Expenditures - The long-term equity investments increased by 353.25% to ¥126,366,670.41 due to increased external investments[7] - The company has invested ¥10 billion to establish a private equity fund, with an initial contribution of ¥2.5 billion completed[21] - The company participated in the establishment of Beijing Zhongxiang Puguang Education Technology Co., Ltd. with a capital contribution of ¥25.5 million, holding a 51% stake[21] - The company invested ¥30 million in Beijing Zhonghai Biotechnology Co., Ltd., acquiring a 7.35% stake, focusing on veterinary vaccines and diagnostic reagents[21] Expenses - Management expenses increased by 29.42% to approximately ¥438.07 million, primarily due to the amortization of the employee stock ownership plan[10] - R&D expenses increased by 36.97% to approximately ¥125.24 million, also due to the amortization of the employee stock ownership plan[10] - Financial expenses surged by 850.20% to approximately ¥1.98 million, mainly due to increased exchange losses from the depreciation of the US dollar[10] - Research and development expenses for the period were CNY 125,236,806.32, an increase of 37.00% compared to CNY 91,435,412.21 in the previous period[32] Shareholder Information - The company's basic earnings per share for Q3 2021 was ¥0.01, down 83.33% year-on-year[2] - The basic and diluted earnings per share were both CNY 0.05, down from CNY 0.22 in the previous period[38] - The company has a total of 63,005,888 shares involved in the employee stock ownership plan, with a purchase price of ¥3.76 per share, totaling approximately ¥236.9 million[21] Other Financial Metrics - The weighted average return on net assets was 0.26%, a decrease of 1.48 percentage points compared to the previous year[2] - The company recognized non-recurring gains totaling ¥7,507,212.75 for the reporting period[6] - The company reported a decrease in tax expenses to CNY 19,767,983.11 from CNY 69,216,114.20 in the previous period, reflecting a significant reduction in tax liabilities[34] - The company experienced a foreign exchange loss of -¥10,107,749.47, compared to -¥14,962,456.57 in the previous period, showing an improvement[42] Audit and Reporting - The report for the third quarter was not audited, indicating that the figures may be subject to change[54]